Question special
Lead Moderator

In the discussion of the paper, reference was made to the recent finding that pharmacologic inhibitors of PARP1 induce substantial objective responses in patients with metastatic prostate cancer expressing homologous recombination DNA-repair defects, thus making a clear treatment path possible. Can you speak on the use of such therapies in current clinical practice and the outlook moving forward in light of this paper's findings?